Summary by Futu AI
WuXi Biologics (Cayman) Inc. submitted the latest monthly report on securities changes to The Stock Exchange of Hong Kong Limited on September 2, 2024, reporting the share changes as of August 31, 2024. The report shows that the company's statutory/registered share capital remains unchanged at a total of 6,000,000,000 shares, with a par value of USD1/120,000 and a total statutory/registered share capital of $50,000. The month-end balance of issued shares is 4,153,329,356 shares, an increase of 46,957 shares compared to the previous month. This increase is mainly due to the exercise of share options, including the pre-IPO stock purchase plan, and the total funds obtained from the exercise of options this month amount to $9,197.06. In addition, the company repurchased and proposed to cancel 1,810,000 ordinary shares on June 11, 2024, which have not yet been canceled as of the report cutoff date. The report also confirms that all securities issuance or sale of treasury shares have been formally authorized and approved by the board of directors, and comply with all applicable listing rules, laws, and other regulatory requirements.